Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

bioMerieux (BMXMF) had Revenue of $4.31B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$4.31B
Net Income	$467.68M
Cost of Goods Sold	$1.91B
Gross Profit	$2.40B
Operating Expenses	$3.67B
Operating Income	$637.14M
Non-Operating Income/Expense	$-10.17M
Pre-Tax Income	$626.97M
Normalized Pre-Tax Income	$626.97M
Income after Taxes	$460.00M
Income from Continuous Operations	$460.00M
Consolidated Net Income/Loss	$460.00M
Normalized Income after Taxes	$460.00M
EBIT	$637.14M
EBITDA	$700.01M
Weighted-Average Shares Outstanding (Basic)	117.92M
Weighted-Average Shares Outstanding (Diluted)	117.92M
Earnings per Share (EPS) (Basic)	$3.97
Earnings per Share (EPS) (Diluted)	$3.94
Balance Sheet Financials
Current Assets	$2.71B
Property, Plant, and Equipment	$1.65B
Long-Term Assets	$3.54B
Total Assets	$6.24B
Current Liabilities	$1.23B
Long-Term Debt	$377.87M
Long-Term Liabilities	$458.92M
Total Liabilities	$1.69B
Common Equity	$4.56B
Tangible Shareholders Equity	$3.23B
Shareholders Equity	$4.56B
Common Shares Outstanding	118.36M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$722.09M
Cash Flow from Investing Activities	$-389.34M
Cash Flow from Financial Activities	$-230.05M
Beginning Cash	$360.77M
End Cash	$478.40M
Increase/Decrease in Cash	$117.62M
Stock-Based Compensation	$25.32M
Common Stock Dividends Paid	$-108.43M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.20
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.08
Debt to Equity Ratio	0.12
Gross Margin	55.66%
Operating Margin	14.79%
EBIT Margin	14.79%
EBITDA Margin	16.25%
Pre-Tax Profit Margin	14.56%
Profit Margin	10.86%
Free Cash Flow	$358.07M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.69
Inventory Turnover	1.70
Receiveable Turnover	3.92
Days Sales in Receivables	93.00
Return on Equity	10.10%
Return on Tangible Equity	14.22%
Return on Assets	7.37%
Return on Investments	9.32%
Book Value Per Share	$38.50
Free Cash Flow per Share	$3.04
Operating Cash Flow per Share	$6.12

Data from Zacks Investment Research, Inc.